Geode Capital Management
SCNI

Geode Capital Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Geode Capital Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14
Closed -$10K – 4928
2022
Q3 		$10K Hold
14
– – ﹤0.01% 4983
2022
Q2 		$16K Hold
14
– – ﹤0.01% 4955
2022
Q1 		$22K Hold
14
– – ﹤0.01% 4922
2021
Q4 		$32K Hold
14
– – ﹤0.01% 4914
2021
Q3 		$30K Hold
14
– – ﹤0.01% 4822
2021
Q2 		$39K Hold
14
– – ﹤0.01% 4679
2021
Q1 		$52K Hold
14
– – ﹤0.01% 4398
2020
Q4 		$38K Buy
14
+8
+133% +$96.8K ﹤0.01% 4204
2020
Q3 		$244K Buy
+6
New +$230K ﹤0.01% 3657

Other funds holding SCNI

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Geode Capital Management's SCNI Position: Q4 2022 in Review

Geode Capital Management sold out of Scinai Immunotherapeutics (SCNI) in Q4 2022, closing a stake of 14 shares — an estimated $10K sold.

Geode Capital Management first reported a position in SCNI in Q3 2020 and held it in 9 quarters. The position peaked at $244K in Q3 2020. 8 funds tracked by Wall St. Rank hold SCNI as of Q4 2022.

  • Geode Capital Management reported no remaining Scinai Immunotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Geode Capital Management sold 14 Scinai Immunotherapeutics shares in Q4 2022, an estimated $10K.
  • Geode Capital Management first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 9 quarters.
  • Geode Capital Management's Scinai Immunotherapeutics position peaked at $244K in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2022.

Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.